Common MS Treatment Wears Off More Quickly in Black Patients
By: Deborah Brauser Black patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to common MS…
Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis
Background Multiple sclerosis (MS) patients experience lower health-related quality of life (HRQoL) than the general population. In clinical trials, natalizumab…
Stuart Schlossman
Native ancestry is associated with optic neuritis and age of onset in Hispanics with multiple sclerosis
Abstract Background and Objective Hispanics with multiple sclerosis (MS) present younger and more often with optic neuritis (ON) as…
Stuart Schlossman
Mayzent, Zeposia May Lose Ground in Canada, Report Finds
MAY 27, 2021 – BY MARTA FIGUEIREDO PHD Click HERE to Subscribe for the MS Beacon eNewsletter Mayzent (siponimod) and Zeposia (ozanimod), the…
Stuart Schlossman
A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping
Barry A Singer,1 Shannon Keith,2 Amy Howerter,3 Helen Doll,3 Timothy Pham,4 Rina Mehta4 1The MS Center for Innovations in Care, Missouri, Baptist Medical Center, St.…
Stuart Schlossman
An MS medication in the Pipeline: UBLITUXIMAB (TG-1101) – A Novel Glycoengineered ANTI-CD20 Monoclonal Antibody
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to…
Stuart Schlossman
Low Sugar Metabolite Associated With Disability and Neurodegeneration in Multiple Sclerosis
May 15, 2021 Summary: Lower serum levels of the sugar metabolite GlcNAc was associated with progressive disability and neurodegeneration in patients…
Stuart Schlossman
Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show
Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active, relapsing forms of multiple…
Stuart Schlossman
Learn about The NARCOMS Registry for Multiple Sclerosis
NARCOMS’ focus is creating and maintaining a database of individuals’ experience with MS and making that information available, both…
Stuart Schlossman
Therini Raises $Millions to Bring Antibody to Myelin-damaging Protein Into Trials
SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ — Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing.…
Stuart Schlossman
